Drug intelligence / Profile preview

adapalene + benzoyl peroxide (Actavis)

Development stage
Unknown
Lead developer
Galderma
Modality
Small Molecules
Administration
Topical
01

Overview

This drug is a topical gel formulation containing a combination of two active ingredients: adapalene (0.3%) and benzoyl peroxide (2.5%). Developed by Actavis Inc. (now part of Teva), it is a generic version of Galderma's Epiduo Forte. Adapalene is a naphthoic acid derivative with retinoid-like activity that binds to specific retinoic acid nuclear receptors (RAR-beta and RAR-gamma) to modulate cellular differentiation, keratinization, and inflammatory processes. Benzoyl peroxide is an oxidizing agent with bactericidal activity against *Cutibacterium acnes* (formerly *Propionibacterium acnes*) and possesses keratolytic and desquamative properties. This combination therapy is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 12 years of age and older.

Brand names
Epiduo ForteTactuPump Forte
Other names
adapalene and benzoyl peroxide gel, 0.3%/2.5%adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.)
02

Targets

RARB (Retinoic acid receptor beta)RARG (Retinoic acid receptor gamma)

Beyond the preview

Go deeper on adapalene + benzoyl peroxide (Actavis).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adapalene + benzoyl peroxide (Actavis).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call